Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More